Payment overview · 2025
General Payments
$676.95
21 reported records · 10 companies
Healthcare provider profile · identity verified
Robert Clay Wood, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BATON ROUGE, LA · NPI 1619955408
Verified facts
What the public records show
CMS Open Payments records show Robert Clay Wood, MD received $676.95 in general payments during 2025 across 21 reported records.
Abbott Laboratories accounted for 48.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $327.74 | 48.4% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $119.80 | 17.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.66 | 7.6% | 3 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $40.86 | 6.0% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $27.83 | 4.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $25.93 | 3.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $25.39 | 3.8% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $23.28 | 3.4% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $20.37 | 3.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.09 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $676.95 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $327.74 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $119.80 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $40.86 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $37.64 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $27.83 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $25.93 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $25.39 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.00 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $20.37 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $20.37 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
84 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 453 | 113 |
| Amlodipine Besylate | Amlodipine Besylate | 265 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 265 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 217 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 208 | 59 |
| Losartan Potassium | Losartan Potassium | 168 | 45 |
| Metformin Hcl | Metformin Hcl | 150 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 148 | 34 |
| Ezetimibe | Ezetimibe | 138 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 122 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 113 | 33 |
| Lisinopril | Lisinopril | 109 | 34 |
| Gabapentin | Gabapentin | 95 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 94 | 37 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 87 | 21 |
| Mounjaro | Tirzepatide | 84 | 19 |
| Montelukast Sodium | Montelukast Sodium | 80 | 22 |
| Doxazosin Mesylate | Doxazosin Mesylate | 77 | 14 |
| Meloxicam | Meloxicam | 73 | 30 |
| Potassium Chloride | Potassium Chloride | 73 | 20 |
| Fenofibrate | Fenofibrate | 72 | 17 |
| Januvia | Sitagliptin Phosphate | 72 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 13 |
| Sertraline Hcl | Sertraline Hcl | 61 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 16 |
| Farxiga | Dapagliflozin Propanediol | 57 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 56 | 14 |
| Alendronate Sodium | Alendronate Sodium | 55 | 14 |
| Memantine Hcl | Memantine Hcl | 55 | 11 |
| Simvastatin | Simvastatin | 54 | 14 |
| Allopurinol | Allopurinol | 52 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | suppressed |
| Bupropion Xl | Bupropion Hcl | 47 | suppressed |
| Ozempic | Semaglutide | 47 | suppressed |
| Alprazolam | Alprazolam | 45 | 13 |
| Trazodone Hcl | Trazodone Hcl | 45 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 44 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | suppressed |
| Furosemide | Furosemide | 42 | suppressed |
| Methocarbamol | Methocarbamol | 42 | 27 |
| Tramadol Hcl | Tramadol Hcl | 40 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 32 |
| Benazepril Hcl | Benazepril Hcl | 37 | 12 |
| Jardiance | Empagliflozin | 36 | 12 |
| Omeprazole | Omeprazole | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 35 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | 11 |
| Colchicine | Colchicine | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Carvedilol | Carvedilol | 29 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 22 |
| Terbinafine Hcl | Terbinafine Hcl | 28 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 26 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 24 | 13 |
| Azelastine Hcl | Azelastine Hcl | 24 | 11 |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 21 |
| Diazepam | Diazepam | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 15 |
| Methylprednisolone | Methylprednisolone | 22 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 20 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | 12 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $676.95 · 21 records | Abbott Laboratories | FREESTYLE LIBRE 3, Fluad, Flucelvax, NURTEC ODT, QULIPTA, REXULTI, UBRELVY, VRAYLAR, Veozah, WATCHMAN FLX, XYOSTED, ZAVZPRET, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error